Methods of preventing cardiovascular events in residual risk dyslipidemic populations
AssigneeKowa Company, Ltd.
InventorsRyu Oshima, Gary Gordon
Life of this patent
Estimating the term…
Abstract
The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.
Claims29
A method of preventing an adverse cardiovascular event in a patient with type 2 diabetes mellitus comprising administering to the patient a therapeutically effective amount of pemafibrate therapy, wherein:
- a) prior to commencing the pemafibrate therapy the patient has an LDL-C concentration ≤70 mg/dL and is on stable statin therapy selected from low to high intensity statin therapy;
- b) the patient has an HDL-C concentration ≤40 mg/dL prior to commencing the pemafibrate therapy;
- c) the patient has a fasting TG concentration ≥200 mg/dL and <500 mg/dL prior to commencing the pemafibrate therapy;
- d) the patient continues the statin therapy after commencing the pemafibrate therapy;
- and
- e) the method prevents the cardiovascular event without decreasing LDL-C concentrations in the patient.
Dependencies are inferred from the claim text.